搜索
Black Diamond Therapeutics Inc
BDTX添加自选
2.010USD
+0.170+9.24%
收盘 07/02, 13:00（美东）报价延迟15分钟
114.46M总市值
亏损市盈率 TTM
关于 Black Diamond Therapeutics Inc 公司
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Black Diamond Therapeutics Inc简介
公司代码BDTX
公司名称Black Diamond Therapeutics Inc
上市日期Jan 30, 2020
CEOVelleca (Mark A)
员工数量24
证券类型Ordinary Share
年结日Jan 30
公司地址245 First Street, 18Th Floor
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编02142
电话16174175868
网址https://www.blackdiamondtherapeutics.com/
公司代码BDTX
上市日期Jan 30, 2020
CEOVelleca (Mark A)
Black Diamond Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Brent M. Hatzis-Schoch, Esq.
Mr. Brent M. Hatzis-Schoch, Esq.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
102.53K
+8.74%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
--
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
--
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
45.04K
+17.56%
Dr. Sergey Yurasov, M.D., Ph.D.
Dr. Sergey Yurasov, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
24.08K
--
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
常见问题
Black Diamond Therapeutics Inc的前五大股东是谁？
Black Diamond Therapeutics Inc 的前五大股东如下：Dr. Ali Behbahani, M.D.
有多少机构持有Black Diamond Therapeutics Inc(BDTX)的股份？
截至2026Q1，共有265家机构持有Black Diamond Therapeutics Inc的股份，合计持有的股份价值约为45.02M，占公司总股份的78.72%。与2025Q4相比，机构持股有所增加，增幅为-14972289.00。